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Summary The effect of the combined administration of doxorubicin (DX) and verapamil (VRP) on the
induction of DX resistance of B16 melanoma cells, was investigated both in vitro and in vivo. Cells grown in
the presence of increasing concentrations of DX and of I1M VRP, tested at several passages, were more
resistant than cells grown with DX alone. The treatment of B16 melanoma bearing mice with the maximal
tolerated dose of DX (12mgkg-1 i.v.) and of VRP (25mgkg-' i.p.) selected a line (B16-DX.VRP)
completely resistant to DX after 17 transplants, while treatment with DX alone selected a DX resistant line
after 27 transplants. Lung metastases were significantly lower in the B16-DX.VRP line compared to the
original B16 melanoma. The results suggest that the association of VRP with DX increases the rate of
resistance development to DX.
The calcium channel blocker verapamil (VRP) has been
shown to enhance anthracyclines, vincristine and vinblastine
cytotoxicity in several resistant cell lines (Tsuruo et al.,
1981, 1983; Slater et al., 1982; Rogan et al., 1984; Simpson et
al., 1984; Pradhan et al., 1984) probably by inhibiting their
active efflux (Tsuruo et al., 1981,1982,1983; Rogan et al.,
1984). Recently we have demonstrated that while the co-
administration of VRP and doxorubicin (DX) is ineffective
in mice bearing tumours against which DX is completely
inactive, this combination may result in a significant
potentiation of DX activity in mice bearing some sensitive
tumours (Formelli et al., 1988). These in vivo results suggest
a potential role of VRP not only after the failure of the
secondary treatment, but also in the initial treatment with
the aim of eliminating the highest number of tumour cells.
Clinical trials combining VRP and DX are in progress both
in DX resistant and responsive tumours (Presant et al., 1986;
Ozols et al., 1987; Kerr et al., 1986) and the use of VRP
with DX from the beginning of tumour treatment poses the
question of the effect of this drug on the onset of DX
resistance. To answer this question we investigated both in
vitro and in vivo the sensitivity to DX of tumour cells
exposed during several transplants to DX alone and to DX
plus VRP. For this purpose we choose the B16 melanoma,
an experimental model which may be representative of a
tumour against which the use of DX plus VRP from the
beginning can be justified. In fact, it has been shown that, in
vivo, B16 melanoma is a DX sensitive tumour whose
sensitivity to DX is significantly increased by co-
administration of VRP (Formelli et al., 1988) and in vitro
VRP enhances DX cytotoxicity in sensitive and resistant B16
melanoma derived sublines (Supino et al., 1986).
Materials and methods
Drugs
DX was kindly supplied by Farmitalia-Carlo Erba (Milan,
Italy) and was dissolved in distilled water immediately before
use. VRP, formulated for clinical use as isoptin (Knoll AG,
Liestal, Switzerland) was diluted in 0.9% NaCl.
In vivo studies
B16 melanoma, obtained from the Division of Cancer
Treatment of the National Cancer Institute (Bethesda, MD,
USA) was maintained by s.c. implant in C57BL/6 male mice
(Charles River, Calco, Italy) of a tumour homogenate
according to the protocols of that Institute (Geran et al.,
1972). Tumour bearing mice were divided into two groups.
At each transplant, when the tumour was palpable (average
tumour diameter= I cm), one group of mice was treated with
DX and the other group with DX plus VRP. DX was
administered i.v. at the dose of 12mgkg-1, which cor-
responds to the highest non-lethal dose for this route and
schedule in non-tumour bearing mice. VRP was administered
i.p. at the dose of 25mgkg-1, which also corresponds to the
highest non-lethal dose. VRP was administered according to
the schedule previously found effective in increasing DX
activity in this tumour (Formelli et al., 1988). It was
administered 3h before DX, since in vitro it potentiates DX
activity in pretreated cells (Supino et al., 1986). It was
administered repeatedly, i.e. 5 days per week, until the
tumour was transplanted, since DX levels are maintained in
this tumour longer than 7 days (Formelli et al., 1988). In
each group the tumour was transplanted when its weight was
4 times the weight at the time of DX administration. The
development of resistance was checked after different
passages by comparing DX activity on the parallel trans-
planted parental B16 line and on the two treated lines
designated B16-DX and B16-DX.VRP respectively. The two
lines were transplanted in mice not treated with DX for one
passage before the anti-tumour activity assays. These assays
were performed by transplanting 106 viable (by trypan blue
dye exclusion) cells s.c. into B6D2Fl mice (according to
Geran et al., 1972) and by treating them with DX i.v.
12mgkg-1, one day after tumour implant. At least 6
animals per group were used. The longest and the shortest
tumour diameters were measured by callipers twice a week
and tumour weight was estimated according to Geran et al.
(1972). Each animal was checked until death. At autopsy
lungs were removed and analysed under a dissecting micro-
scope. The number of metastases per lung were counted, the
two diameters of individual metastases were measured and
their weight estimated according to Geran et al. (1972).
Statistical analysis of the number and weight of metastases
was evaluated by the Mann-Whitney U test (2-tailed). To
assess antitumour activity, tumour growth delay (T-C) and
median survival times (MST) were also evaluated. T-C is the
difference, in number of days, required for the tumours to
reach 1g, between treated and control mice. From the
evaluation of the significance (Student's t test) of the
difference of the tumour weights of treated and control mice
3 weeks after tumour implant a T-C>4 days corresponds to
a significant reduction of tumour weight. The significance of
the difference of MST in the different groups was evaluated
by Student's t test.
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In vitro studies
A B16 melanoma cell line (Bl6V) obtained from the murine
B16 melanoma and grown as previously described (Supino et
al., 1986) was exposed to continuous increasing concen-
trations of 10ngml-1 DX at almost every passage with or
without VRP 1 uM (equivalent to 0.454jgml-1). These two
cell lines were designated B16V-DX.VRP and B16V-DX
respectively. Control cells were maintained in DX-free
medium with or without VRP 1MM. The sensitivity of the 4
cell lines (Bl6V, B16V-VRP, B16V-DX and B16V-DX.VRP)
was checked in parallel after different passages from the
starting of exposure to DX. A detailed description of the
cytotoxicity assay for the evaluation of the resistance index
(RI) has been previously reported (Supino et al., 1986).
Briefly, cells were treated at cell seeding with different
concentrations of DX. After 72h, cells were harvested by
trypsinization and counted in a Coulter Counter (ZBI,
Electronics, Luton, UK) and cell viability was evaluated by
trypan blue dye exclusion. The RI was evaluated as the ratio
between the graphically determined concentrations causing a
50% decrease in viable cell number (ID 50) on B16V-
DX.VRP and B16V-DX and the ID 50 on B16V cells.
For cell morphology analysis, cells seeded 48h before were
photographed with an inverted Leitz microscope fitted with
phase-contrast optic.
Results
In vitro development ofdrug resistance
The results of the sensitivity assays performed in parallel on
B16V-DX and B16V-DX.VRP in 2 separate resistance
inductions are reported in Table I. Cells grown in VRP
containing medium, B16V-VRP, showed no differences in
sensitivity to DX compared to cells grown in drug-free
medium (ID 50: 14ngml-1 vs. lI + 1.9ngml-1). The increase
of DX concentration in the medium of BI6V-DX and B16V-
DX.VRP led to an increase in the RI which was higher if
cells were grown in the presence of 1MM VRP. In fact, the
cytotoxic effect of similar doses of DX in the two lines was
statistically different (P.0.05 Student's t test) in all the assays
performed. In the first experiment performed, it was not
possible to evaluate DX cytotoxicity in the B16V-DX.VRP
line when DX concentration was 100 ngml- because the
line was lost due to cessation of cell replication. In the
second experiment, when DX concentration in the medium
was lOOngml-1, B16V-DX.VRP cells started to slow their
replication until no further proliferation was observed and
the cell line was lost after few passages. No sign of toxicity
was evident in both experiments before cessation of cell
Table I Resistance index of B16V cells grown in the presence of
increasing concentrations of DX with and without VRP
B16V-DX B16V-DX.VRP
DXa Passage ID50b ID50b
Induction (ngml 1) No. (ngml 1) Rf (ngml-1) RT
1 50 7 200 18 320 27
100 21 400 34 ND
2 50 6 280 25 410 37
80 11 370 34 540 49
100 16 420 38 950 86
'DX concentration in the culture medium at the time of cytotoxic
assay; bDose inhibiting the 50% of the growth. The ID50 was
l±l+.9ngml-1 for B16V cells and 14ngml-I for B16V-VRP tested
at the 11th passage; cResistance index: ID50/ID50 on B16V cells;
ND =not detectable because the cell line was lost due to cessation of
replication.
proliferation. Morphological alterations of B16V-DX.VRP
cells, possibly associated with the decrease of cell pro-
liferation, were already present at earlier passages, when DX
concentrations in the culture medium were 80ngml-1. At
that time (passage 11) no differences in cell morphology were
evident between the untreated parental line B16V (Figure la)
and the subline B16V-VRP (Figure lb). B16V-DX cells
(Figure lc) were larger and more melanotic than B16V and
BI6V-VRP cells, although the cell morphology of the two
sublines was similar. All these cells, B16V, B16V-VRP and
B16V-DX, showed a bipolar morphology characteristic of
melanoma cells. Cells of the B16V-DX.VRP subline showed
marked cell flattening (Figure ld) indicative of increased cell-
substrate adhesiveness, increase in melanin content,
hypertrophy and filamentous 'dendrite'-like elements.
In vivo development ofdrug resistance
The activity of DX (12mgkg-1 i.v.), was tested in mice
transplanted s.c. with 106 cells of the original B16 melanoma
and of the B16-DX and B16-DX.VRP lines after 7, 17 and
27 transplants in mice treated with DX (12mgkg-1 i.v.)
alone or DX plus VRP (25mgkg-1 i.p.). The sensitivity of
the three tumour lines was assayed by treating tumour
bearing mice on day 1 after tumour implant; the sensitivity
of the original B16 melanoma was also tested by starting the
treatment when the tumour was palpable (on day 7), in
order to assess the sensitivity of this experimental system
also according to clinical end points. The results are reported
in Table II and in Figure 2, the latter reporting the time
course of tumour growth of control and treated mice. In
mice bearing B16 melanoma, DX treatment on day 1 caused
a significant delay in tumour growth (Figure 2) and this
effect corresponds to a 1.3 log1o cell kill calculated ac-
cording to Corbett et al. (1984) from the T-C and from the
average tumour doubling time of controls. A significant
increase in life span (Table II) was also observed, even if
lower than that (T/C.125%) considered necessary to
demonstrate activity (Geran et al., 1972). If the treatment
was given on day 7, there was a significant reduction in the
growth of the tumour, but no partial or complete regression
(Figure 2); a significant increase in life span was also
observed (Table II). At autopsy, only animals treated on
day 1 had a lower number of metastases than the controls
(Table II).
B16-DX and B16-DX.VRP lines tested after 7 transplants
in treated mice were still sensitive to DX treatment and their
sensitivity was similar (data not shown).
After 17 transplants the B16-DX line was still slightly
sensitive, even if less than B16, since DX treatment caused a
significant delay in growth (Figure 2) and increase in life
span (Table II). In mice bearing the B16-DX.VRP line at the
17th transplant, DX treatment was completely ineffective
(Figure 2 and Table II) and therefore the association of VRP
to DX caused an earlier onset of complete resistance to DX.
In mice bearing the B16-DX.VRP line the number and
weight of lung metastases at death was statistically lower
compared to mice bearing B16. In DX treated mice the
number of metastases was not reduced compared to controls
in both lines (Table II).
After 27 transplants in treated mice, B16-DX also became
completely resistant to DX and B16-DX.VRP maintained its
resistance (Figure 2 and Table II). The tumorigenicity of
B16-DX.VRP may have been slightly reduced since there
was 1 no take out of 7 implanted tumours. Moreover, the
latency of B16-DX.VRP was heterogeneous, being the
tumours palpable (=0.1 g) later than 20 days after tumour
implant in 2/7 mice (data not shown) with consequent longer
range of the survival time (Table II). The number of
metastases of the B16-DX.VRP line was still reduced
compared to the original B16 and DX treatment did not
affect them (Table II).VRP POTENTIATION OF DX RESISTANCE IN B16 MELANOMA CELLS 345
Figure 1 Morphology of B16 cell lines. (a) B16V, untreated parental line; (b) B16V-VRP, line grown in the continuous presence
of VRP 1 yM; (c) B16V-DX, line grown in the presence of increasing concentrations of DX; (d) B16V-DX.VRP, line grown in
the continuous presence of VRP 1 yM and of increasing concentrations of DX. All photographs were taken at the 11th passage,
48 h after cell seeding. In the lines grown in the presence of DX the drug concentration in the culture medium was 80ngml-'.
Final magnification: 1:200.
Table II Activity of doxorubicin in mice bearing B16 melanoma and B16-DX and B16-DX.VRP lines
Lung metastasesd
No. of Median
Tumour mice with Median weight
line Transplant Treatmenta T-Cb MSTc metastases No. (range) mg (range) No. takese
B16 - - 33(22-41) 9/9 100 (2->200) 161 (1-476) 0/9
DX(+ 1) 10 40(35-49)g 9/9 39(13-117)h 30 (5-140)h 1/9
DX(+7) 5 40(27-48)f 9/9 100(48->200) 131 (19-1167) 0/9
B16-DX 17 - 29(22-34) 7/7 17 (3-125) 55 (1.0-204) 0/7
DX(+ 1) 5 34(24 44)f 6/6 57 (3-100) 70 (0.6-239) 0/6
27 - 29(18-39) 7/7 50 (1-150) 2 (0.5-383) 0/7
DX(+1) 1 34(17-44) 4/6 64 (0->200) 135 (0-1000) 0/6
B16-DX.VRP 17 - 26 (17-29) 6/6 5 (1-20)' 0.4(0.10-188)' 0/6
DX(+1) 1 22(19-33) 6/6 4 (2-8) 0.9(0.01-4) 0/6
27 - 34(23-62) 6/6 4 (3-30) 1.7(0.60-55) 1/7
DX(+ 1) 0 30(23-44) 6/6 48 (1-96) 2.5(0.06-5) 0/6
aB6D2Fl mice transplanted s.c. with 106 cells were treated with DX 12mgkg1 i.v. on day 1 or 7 after tumour implant;
bAverage tumour growth delay in days; cMedian survival time in days and range; dMetastases were evaluated at death as
number of mice with metastases, median number and range and median weight and range; eNumber of mice without tumour
evaluated 3 months after tumour implant; fP<0.OS; 9P<0.01 vs. controls Student's t test; hp<0.05 vs. controls; IP<0.05 vs.
B16 controls Mann-Whitney U test.
Discussion
Although the acquisition of tumour drug resistance is pres-
ently far from being understood, its development is apparently
due to the elimination of drug sensitive cells, leaving pre-
existing drug resistant cells to predominate. Previous studies
on B16 melanoma cells, never exposed to DX before, have
shown that VRP, at the doses employed in this study,
induces a 1.5-fold increase of DX cytotoxicity in vitro
(Supino et al., 1986) and also a significant increase of DX
antitumour effect in vivo (Formelli et al., 1988). The in vitro
studies (Supino et al., 1986) indicated that the B16V line346 F. FORMELLI et al.
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Figure 2 Effect of DX on the growth of B16 melanoma and
B16-DX and B16-DX.VRP sublines after 17 and 27 transplants:
* * controls; *---@ DX 12mgkg-1 i.v. on day 1; E---E
DX 12mgkg-t i.v. on day 7. T indicates the day of treatment.
*P.0.001 Student's t test compared to controls.
originally included 20% of DX-resistant cells and the
increase of DX cytotoxicity on this line may be due to an
effect of VRP on these pre-existing resistant cells, possibly
the ones of lower resistance index. In fact it has been shown
that VRP can completely reverse DX resistance of human
ovarian cancer cells, but only if the degree of resistance is
moderate (3-6 fold) while it only partially reverses the
resistance of highly (150-fold) resistant cells (Rogan et al.,
1984). Similar considerations apply to previously reported in
vivo results (Formelli et al., 1988). As we have shown in this
paper, B16 melanoma is sensitive to DX since tumour
growth is significantly delayed, but this effect corresponds to
a limited cell killing (1.3 logl0) and to a low increase of
survival time. If mice are treated when the tumour is
palpable, there is no tumour regression and therefore,
according to clinical end points, this experimental model is
resistant to DX. This suggests that there are pre-existing cells
resistant to the concentration of DX achievable in vivo and
that VRP can increase the efficacy of these concentrations of
DX, possibly by acting on cells with a low degree of
resistance. Consequently, the repeated treatment with DX
plus VRP both in vitro and in vivo, which results in a higher
cell killing maybe due to death of cells with a lower
resistance index, leads to a quicker selection of the more
resistant cells. Since it has been reported that VRP inhibits
DX efflux from resistant cells (Tsuruo et al., 1983; Rogan et
al., 1984) it is possible that this higher cell killing is due to
an increase of intracellular DX concentrations and therefore
the increased levels of resistance might be due to the fact
that cells had been exposed to higher DX concentrations.
It is interesting to note that cells selected by DX plus
VRP, besides being more resistant compared to those
selected by DX alone, developed features associated with
more differentiated cells. In fact, in vitro they showed
marked cell-substrate adhesiveness, higher melanin content
and a higher number of dendrite-like structures, which are
all characteristic markers of normal differentiating
melanocytes (Hirobe, 1978). Similar observations of
normalization of cell morphology have been previously
reported by DX alone on B16 melanoma cell lines (Raz,
1982) and on other cell lines made resistant to daunomycin,
vincristine and actinomycin D (Biedler et al., 1975). In vivo
the B16-DX.VRP line was slightly less tumorigenic and, as
previously reported for B16VDXR, a B16 melanoma line
resistant to DX both in vitro and in vivo (Formelli et al.,
1986), it showed a longer and more heterogeneous latency
compared to B16. Moreover, similar to the B16VDXR line
(Formelli et al., 1986), the B16-DX.VRP line produced a
significantly lower number of metastases compared to the
original B16 tumour. Therefore, the results reported here
and previously (Formelli et al., 1986) show that selection by
DX both in vitro (B16VDXR line) and in vivo with the
addition of VRP (B16-DX.VRP line) leads to cells with
diminished metastatic potential. A similar observation of
decreased metastases in a B16-BL6 line made resistant to
DX both in vitro (B16VDXR line) and in vivo with the
The high degree of cell substrate adhesiveness observed in
vitro and the reduced metastatic potential found in vivo
suggest that, as reported for other resistant cells, in these
cells also, plasma membrane may mediate the expression of
drug resistance (Biedler et al. 1975; Kartner et al., 1983). In
this regard, it must be pointed out that the effect of VRP as
well as that of other agents not affecting calcium levels, but
known to circumvent pleiotropic drug resistance, is
associated with their interaction with the cell membrane
(Ramu et al., 1984; Hindenburg et al., 1987).
In conclusion, the results of this study suggest that the
association of VRP with DX may increase the rate of
resistance development to DX. This finding might have
potentially important clinical implications particularly for
such tumours as small cell lung cancer, a tumour whose
sensitivity to DX in association with VRP is currently under
test (Kerr et al., 1986) and whose high relapse rate is prob-
ably due to acquisition ofdrug resistance (Smyth et al., 1985).
The authors thank Dr Giorgio Parmiani for his critical reading of
the manuscript.
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